Users of this system, can login to view this document.

Login

Enter the following information to request a copy of the document from the responsible person.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

This email address is used for sending the document.